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1. INTRODUCTION
The objective of any drug delivery system is to provide therapeutic amount
of drug to targeted site in body to achieve the desired therapeutic effect. In recent
years, attention has been focused on the development of new drug delivery system
rather than invention of new molecules. Because the development cost for new drug
molecule is very high and possibility of repenting successful drugs by applying
concepts and techniques of controlled release drug delivery systems.
CONVENTIONAL DRUG DELIVERY SYSTEM
Oral drug delivery is the most widely utilized route of administration among
all the routes that have been explored for systemic delivery of drugs via
pharmaceutical products of different dosage forms.
The oral dosage form has survived due to
1. Relatively simple and inexpensive to make
2. Convenient for the patient
3. Technology is easy to adapt to changing needs of the drug substance
4. Simplifies the regulatory approval process.
Pharmaceutical products designed for oral delivery are mainly conventional
drug delivery systems, which are designed for immediate release of drug for rapid or
immediate absorption1.
Limitations of the Conventional Drug Delivery System
1) Drugs with short half-life require frequent administration, which increases
chances of missing the dose of drug leading to poor patient compliance.
2) A typical peak-valley plasma concentration-time profile is obtained which makes
attainment of steady state condition is difficult.
3) The unavoidable fluctuations in the drug concentration may lead to under
medication or overmedication as the steady state concentration values fall or rise
beyond the therapeutic range.
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4) The fluctuating drug levels may lead to precipitation of adverse effects especially
of a drug with small therapeutic index, whenever overdosing occurs.
In order to overcome the drawbacks of conventional drug delivery systems,
several technical advancements have led to the development of controlled drug
delivery system that could revolutionize method of medication and provide a number
of therapeutic benefits2.
For curing of disease, it is necessary to achieve and maintain the
concentration of administered drug within the therapeutically effective range, for
this drug dosage must be taken several times which results in fluctuating drug levels
in plasma. This drawback of conventional dosage form can be overcome by
formulation of controlled release dosage forms which provides drug release in an
amount sufficient to maintain the therapeutic drug level over extended period of
time, with release profiles controlled by the special technological construction and
design of the system.
The primary objectives of controlled drug delivery are to ensure safety and
enhancement of efficacy of drug with improved patient compliance. So the use of
these dosage forms are increasing in treatment of acute and chronic diseases as they
maintain the concentration of drug in plasma above minimum effective
concentration and below the minimum toxic level for extended period of time. Thus,
controlled drug delivery results in optimum drug therapy with reduced frequency of
dosing and side effects.
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Figure No. 1 Immediate versus controlled release
Controlled Drug Delivery1
For many drugs, the basic goal of therapy is to achieve a steady state blood
or tissue level i.e., therapeutically effective and non toxic, for an extended period of
time. For this purpose controlled release dosage forms are designed.
Sustained release, sustained action, prolonged action, controlled release,
extended action, timed release depot and repository dosage forms are terms used for
identifying drug delivery systems, which achieve prolonged therapeutic effect by
continuous release of drug for extended time after single dose administration.
controlled release systems release drug at predetermined rate and sustained release
systems only prolong the drug release.
Advantages of controlled release dosage dorms
Controlled release preparations offer several advantages over immediate
release conventional dosage form of same drug.
1. More efficient drug utilization by the body.
2. Better patient compliance.
3. Decrease in frequency of administration.
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4. Elimination of peak and valley plasma levels so that drug concentration is
maintained constant over a long period. Hence, reduction in severity and
frequency of untoward effects.
5. Safety margin of potent drug is increased.
Disadvantages of controlled release dosage forms
1. Overdose: Being multiple preparations, there is always the possibility of
sudden release of the total dose administered i.e. dose dumping, which may
result in some toxic manifestations.
2. Loss and Flexibility in dosage: - It is very difficult to adjust the dose of
controlled release products to a patient’s response. The physician has less
flexibility in adjusting the dosage regimen.
3. Side effects: - Controlled release preparations would show not only a longer
duration of effect but also a long duration side effects, especially if patient is
hypersensitive to given medication.
4. The cost of unit dose of controlled release system is higher than the regular
conventional dosage forms.
5. Special treatment problems may arise during accidental poisoning with these
systems.
Oral Controlled Drug Delivery System4
Oral route has been commonly adopted and most convenient route for the
drug delivery, as the patient acceptance for oral route is high. It is relatively safe
route of administration than most parenteral routes where the constraints of sterility
and potential damage at site of administration are minimal. Controlled release
preparation release the drug in controlled manner in gastrointestinal tract for
systemic uptake.
As there is more flexibility and received more attention in designing of
dosage form for oral route than drug delivery design for other routes.
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Oral controlled delivery systems can be broadly classified into following
categories, depending on their mechanism of drug release
1. Dissolution – controlled release
a. Encapsulation dissolution control.
b. Matrix Dissolution control.
2. Diffusion  Controlled Release
a. Reservoir devices
b. Matrix devices
3. Water penetration Controlled
a. Osmotically controlled release
b. Swelling Systems.
4. Ion exchange resins
5. Gastro retentive Systems
6. Bio adhesive drug delivery systems.
7. Microspheres.
8. Spheronization/ Pelletization
9. Coating Technologies.
Dissolution Controlled Release System5
This can be obtained by slowing the dissolution rate of the drug. Slowing
of dissolution rate can be achieved by incorporating the drug in an insoluble
polymer and coating drug particles or granules with polymeric materials of varying
thickness.
Also the drug may be incorporated in hydrophobic or hydrophilic matrix.
The rate of penetration of dissolution fluid into matrix controls the rate of drug
availability. Also the porosity of compressed structure is important parameter.
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Matrix Formulations6
Matrix formulations are defined as a drug or other active ingredient
embedded in insoluble excipients in order to achieve release by a continuous
leaching of the drug from the inert matrix core.
Matrix systems can be divided into three types
1. Monolithic matrix tablets
2. Gel forming hydrophilic matrix tablets
3. Erodable (hydrophobic) matrix tablets
Inert monolithic matrix tablets
Probably the simplest method of obtaining controlled release of a drug from
an oral dosage form is incorporation of a drug in an inert matrix. In this inert means
non interacting with the biological fluids. The main reason for its popularity is that
drug release from plastic matrix tablets is independent on the state and condition of
the digestive juices, which may show large inter and intra patient variability (pH,
viscosity).
During its transit through the gastro-intestinal tract, the porous matrix tablet
does not disintegrate like conventional tablets, but remains intact and the skeleton
can be recovered in faeces. The materials used in the preparation of these inert
matrices are predominantly (insoluble) polymers and lipophilic compounds. The
first polymers to be used for the preparation of matrix tablets were (semi- synthetic
polymers such as polyethylene, poly vinyl chloride, poly methyl methacrylate,
polystyrene, poly vinyl acetate, cellulose acetate and ethyl cellulose. The fat
compounds used included carnauba wax, hydrogenated castoroil, and tri stearin.
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Major drawback of most of the inert polymeric matrix tablets were their
inherent  first order drug release characteristics, their poor direct compression
characteristics and the problem leaning of agglomeration equipment used for the
preparation of agglomerates with the required compression characteristics.
Mechanism of release of inert monolithic matrix tablets10
Release from inert matrix tablets occurs via a leaching mechanism. Drug
particles dispersed in the polymer matrix dissolve in the penetrating gastro-
intestinal fluids and are released from the tablet by diffusion through the porous
network of already existing pores and pores that created by dissolution of the drug
particles. At drug loadings exceeding approximately 10-15 % volume, a continuous
structure connecting all drug particles exists (percolating drug network). At
considerably lower loadings, a particular fraction of the drug may be completely
surrounded by the polymer matrix (trapped fraction), which would result in
incomplete release.
Figure: 2 Schematically representation of a leaching-based release mechanism.
Solvent activated matrix tablets
The use of solvent-activated matrix tablets as a method to obtain zero order
release i.e. constant release rates over an extended period was first proposed by
Hopfenberg. Solvent-activated drug delivery system is a collective term comprising
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those systems in which the interact ion between polymer and water is responsible
for achieving controlled release. The interaction with water may include
plasticization, swelling, dissolution, erosion or degradation of the polymer. The
two most important types of solvent activated matrix tablets are gel-forming
hydrophilic matrix tablets and erodible (hydrophobic) matrix tablets.
Gel-forming hydrophilic matrix tablets
Gel-forming hydrophilic or swellable matrix systems are homogeneous or
heterogeneous systems in which the drug is dispersed in a swellable hydrophilic
polymer. These systems have been widely studied by researchers since they offer
the possibility to obtain a constant drug delivery over an extended period of time.
Drug release is a function of the polymer characteristics.
Upon swallowing gel-forming hydrophilic matrix tablets, the hydrophilic
polymer is plasticized by the aqueous gastro-intestinal due to which undergoes
macromolecular chain relaxation and volume  expansion.  Consequently, upon
penetration of the gastro-intestinal fluids into tablet, a sharp front can be
distinguished which separates a dry, glassy core from a hydrated and rubbery gel
layer. Release is governed by diffusion of the dissolved drug through the swollen
gel layer and generally shows a burst effect, caused by dissolution and leaching of
drug particles present at the surface prior to formation of the release-controlling gel.
Other swellable polymers, which have been applied in swelling-controlled
oral drug delivery systems, which show solvent controlled release, are guar gums,
xanthan gum, poly (ethylene oxide) (PEO), poly (vinyl alcohol), ethylene-vinyl
alcohol copolymers (EVA) and dextrans.
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Erodible matrix tablets
Erodible polymers such as poly anhydrides offer another interesting
material platform for zero-order drug release. Like several HPMC grades, upon
water penetration, poly anhydrides form a gel-layer, which erodes at a specific rate.
By choosing the right polymer composition the thickness of the gel-layer may
remain constant with time resulting in a constant release rate until depletion of the
drug.
12
In the last two decades, controlled-release dosage forms have made
significant progression terms of clinical efficacy and patient compliance.
Preparation of drug- embedded matrix tablet that involves the direct compression
of a blend of drug, retardant material and since additives is one of the least
complicated approaches for delivering drug in a temporal pattern into the systemic
circulation. The matrix system is commonly used for manufacturing controlled
release dosage forms because it makes such manufacturing easy. A wide array of
polymers has been employed as drug retarding agents each of which presents a
different approach to the matrix concept. Polymers forming insoluble or skeleton
matrices constitute the first category of retarding materials, also classed as plastic
matrix systems.
The second class represents hydrophobic and water-insoluble materials,
which are potentially erodible, while the third group includes polymers those form
hydrophilic matrices.
Plastic matrix systems, due to their chemical inertness and drug embeding
ability, have been widely used for controlling the release of the drug. Liquid
penetration into the matrix is the rate-limiting step in such systems unless
channeling agents are used. The hydrophobic and waxy materials, on the other
hand, are potentially erodible and control the release of drug through pore diffusion
and erosion. Polymers belonging to hydrophilic matrix systems, when exposed to
an aqueous medium, does not disintegrate, but immediately after hydration
develops a highly viscous gelatinous surface barrier, which controls the drug
release from, and the liquid penetration into the center of the matrix system.
13
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The use of hydrophilic polymers is actually the most used method in
controlling the release of drugs in the formulation of oral pharmaceutical dosage
forms. Hydroxy propyl methyl cellulose has been extensively used since the
early1960s as a rate-controlling polymer in oral extended-release dosage forms.
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Hydrophilic matrix systems are popular and versatile controlled release
system amongst polysaccharide derivatives like cellulose ethers, e.g. ,hydroxyl
propyl methyl cellulose (HPMC) and a diverse range of other materials, including
sodium alginate, carrageenan, chitosan, and xanthan gum.
Diffusion Controlled Release System
In case of diffusion controlled release system, diffusion of drug molecule
through the polymeric membrane is the rate limiting step. These systems can be
prepared by encapsulating the drug particles in polymeric membrane or by
dispersing the drug in polymeric matrix.
These systems exhibit non-zero order release rate due to increase in diffusion
resistance and decrease in effective diffusion area as the release proceeds.
Water Penetration Controlled Release System
In these systems, control release is obtained by the penetration of water
into the system. There are following types of water penetration controlled release
system,
Osmotically Controlled Release System
In this system delivery of drug is controlled by solvent influx across a
semi permeable membrane which carries the drug outside through a laser drilled
orifice.
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The osmotic and hydrostatic pressure differences on either side of semi
permeable membrane causes fluid transport into the system, so the rate of drug
release is dependent on osmotic pressure of formulation.
Swelling Controlled Systems11
These systems are initially dry and when placed in body absorb water or
other body fluids and swell. The drug is diffused through the swollen network. Thus,
swelling and diffusion controls the release rate. Most materials used in swelling
controlled systems swells without dissolving.
Ion Exchange Resins
The drugs which are susceptible for enzymatic degradation can be
formulated using ion exchange resins as they temporarily protect the drugs. Resins
are water insoluble materials having anionic, cationic groups. Complex of resin and
drug is formed by prolonged exposure of drug to resin. In ionic environment drugs
are displaced from the resin. The release rate is proportional to the concentration of
ions present in the vicinity of administration site.
Gastro retentive systems
These are hydro dynamically balanced systems. In these systems dosage
form have the specific gravity less than gastric juice, so they float in stomach and
retain the drug over there for extended period of time. Thus, total residence time in
stomach is increased. Also these systems are relatively large in size and passing
from pyloric opening is prohibited.
This system is useful for drugs which are absorbed in stomach and also for
local action of drug.
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Bio adhesive Systems
Bio-adhesion is the attachment of synthetic or biological macromolecules to
biological tissue. When bio-adhesion occurs with the mucus layer then it is called as
mucoadhesion.
This type of dosage form results in
 Prolonged residence time within specified region of body and provides
intimate contact with absorbing membrane.
 Localization of the drug delivery system at given target site.
 An increase in drug concentration gradient due to contact of drug particles
with mucosal surface.
 Thus the combined effects of direct drug absorption and decrease in
excretion rate causes increased bioavailability and duration of action with
smaller dosage and less frequent administration.
Microspheres
These are monolithic, homogenous, spherical particles uniformly covered
with polymer film. The size ranges from 0.1–100µm. They are widely used as drug
carriers.
Administration of drugs in the form of microspheres causes
 Improvement of treatment as localization of active substance occurs at site of
action.
 Prolongation of drug release.
 Protection of sensitive drugs such as protein and peptides from chemical and
enzymatic degradation.
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Microspheres are prepared by following methods,
 Emulsion – solvent evaporation (o/w, w/o, w/o/w)
 Phase separation (non-solvent addition, and solvent
partitioning)
 Interfacial polymerize
 Spray drying.
The lactide glycolide homo and copolymers are mostly used for preparation
of microspheres, which depending upon variation in copolymer ratio modulates the
release.
Spheronization / Pelletization Process
This is one of the newer processes for formulation of oral controlled release
dosage forms. Formulation of controlled release pellets, beads or spheres are
advantageous than single unit dosage forms. They minimize, dose dumping i.e.
unexpected drug release as in case of single unit dosage form. The beads and pellets
can be combined to get the multi particulate dosage form which provides customized
release profiles. Also incompatible drugs can be delivered by multiparticulate
system. Following are the basic methods for pellets or bead production.
a. Microencapsulation
b. Spray congealing
c. Formulation of particles from plastic mass
d. Agglomeration.
Coating Technologies
Coating technology involves the deposition of uniform membrane of
polymer onto the surface of the substrates such as tablets, pellets and drug particles.
Coating of polymers on substrates provides controlled release using following
techniques
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a. Film coating
b. Layering coating
c. Compressed coating
Film coating is performed in a coating pan, a fluidized bed or a rotary
granulator. Ethyl cellulose, methacrylic ester copolymers, methacryl ester
copolymers, cellulose acetate and enteric polymers are used for film coating either
alone or in combination.
Factors influencing the design of oral controlled drug delivery systems
The pattern of release of drug from dosage form in the body is dependent on
the drug properties. So these properties of drug like physicochemical and
physiological must be taken into account before the design of controlled release
dosage form.4
Physicochemical Factors
Molecular weight of the drug
Diffusivity is the ability of drug to pass through the membrane and is
inversely proportional to the molecular size. So the lower the molecular weight
faster and more complete is the absorption. Mostly drugs are absorbed through the
passive diffusion and the upper limit for passive diffusion is 600 Daltons. So drugs
having higher molecular weight are poor candidates for oral controlled release
systems. e.g. proteins and peptides.3
Dose Size
In controlled release system, the dose is addition of 2-3 doses depending
upon objective. That is single dose or twice daily. So the drugs have dose more than
500 mg are unsuitable because the bulk for controlled system will be large.16
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Aqueous solubility of drug
A drug with good aqueous solubility, especially with pH – independent
solubility acts as good candidate for controlled release systems. The aqueous
solubility of drug influences the dissolution rate so that controlled release system
cannot control the absorption process, so poorly aqueous soluble drugs are poor
candidates for controlled release. Since drugs must be in solution form before they
are absorbed, drugs with low solubility limit dissolution and suffer bioavailability
problems e.g. griseofulvin. Also for drugs having high solubility, it is difficult to
reduce dissolution rate and ultimately the absorption.
Drug PKa
The PKa range for acidic drugs whose ionization is pH sensitive is 3-7.5
and for basic drugs is 7–11, so for optimum passive absorption the drugs should be
non-ionized at site at least to an extent of  0.1 – 5%.
Therefore, drugs which are largely ionized are poor candidate for
Controlled Release System.
Partition coefficient
When the drug is ingested, it has to cross many biological membranes for
absorption and also for elimination. The ability of drug is to penetrate these lipidic
membranes is appearant partition coefficient which is defined as,
w
o
C
C
K 
Where,
K = apparent partition coefficient
Co = concentration of drug in non-aqueous phase
Cw = concentration of drug in aqueous phase
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Drugs with high partition coefficient value easily permeate through
biological membrane, but for further functions aqueous solubility is required. So
there must be balance between aqueous and oil solubility of drug. This balance gives
optimum flux for permeation through biological membranes. Thus, drugs with
extreme partition coefficient are undesirable for formulation of controlled release
system.
Drug Stability
The stability of drug at site of release and its exposure to bio membrane,
influence the design of controlled release system. Drugs that are unstable in stomach
pH can be formulated as slow release product, which release the drug only in
intestinal environment. Drugs that undergo gut wall metabolism and show instability
in small intestine are poor candidate for controlled release system. In such case drug
must be chemically modified or other route of administration is preferred.6
Protein Binding
The duration of action of drug is function of protein binding. Drug – protein
complex serves as sustaining depot for drugs having high protein binding capacity.
However, drugs with high protein binding capacity are unsuitable for controlled
release system, as they have got long elimination half lives.5
Physiological Factors
Absorption
The constant blood or tissue concentration of drug is obtained from
controlled release system only when the drug is uniformly released and absorbed.
The release rate of drug from dosage form is the rate limiting step rather than
absorption and rapid absorption relative to release is essential. So the drugs which
are poorly absorbed are poor candidates for controlled release system. The drugs
absorbed at special sites of gastrointestinal tract are also poor candidate.
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Distribution
For design of controlled release system, all possible information about drug
disposition must be known. But decisions are done by considering the some
pharmacokinetic parameters, one of which is apparent volume of distribution.
Apparent volume of distribution gives the magnitude of drug distribution and
protein binding within body. Also it influences the concentration of drug in blood
and tissue and elimination kinetics.6 So, that the drugs having high apparent volume
of distribution are poor candidates for controlled release system.
Metabolism
Metabolism of drugs is either an inactivation of active drug or conversion
of an inactive drug to active metabolite. The pharmacokinetic parameters like
elimination rate constants (Ke) are used to predict the rate and extent of metabolism
of drug, so they are considered in design of controlled release system. Following are
the two important factors related to metabolism which must be considered during
design of controlled release system,
1. For chronic administration, drugs capable of either inducing or inhibiting
enzyme synthesis are poor candidates for controlled release system due to
difficulty of maintaining uniform blood levels.
2. Drugs undergoing first pass effect or intestinal metabolism are not suitable
for design of controlled release system.6
Duration of Action
Duration of action significantly affects the design of controlled release
system and is dependent on biological half life (t ½).The factors like elimination,
metabolism and distribution influence the half life. So, a drug with shorter half life
require frequent dosing, making it suitable candidate for controlled release system.
But drugs with long half life acts for longer time so they are unsuitable. Drugs with
half life less than 2 hrs should not be used because a very large dose will be required
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to maintain the release rate. Drugs with half life in range of 2-4 hrs make a good
candidate for design of controlled release system.4
Side Effects
Due to fluctuations in plasma drug concentration, side effects are
developed. The incidences of side effects can be minimized by controlling the
concentration within therapeutic range at any given time. Thus, controlled release
system reduces the side effects by maintaining the plasma concentration in
therapeutic range.
Eg. The gastric irritation caused by drugs like aspirin, potassium chloride
reduced due to controlled release.
Margin of Safety
Margin of safety is known by considering the therapeutic Index.
50ED
50TDIT 
Where,
T I     = Therapeutic Index
TD50 = doseicmedian tox
ED50 = doseeffectivemedian
The drug is considered relatively safe, if its TI is more than 1. The drug is
considered to be more safer as its TI value increases. TI gives the range of plasma
concentration between which drugs are safe and effective. Drugs with narrow
therapeutic range require precise control over blood levels of drug so that they are
unsuitable for controlled release system.3,6
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Disease State
In certain cases disease state is important property for considering a drug for
controlled release dosage form e.g. aspirin which is not suitable candidate for
controlled release dosage Form but its controlled release dosage Form maintain
therapeutic concentration particularly over night and thus alleviating morning
stiffness in Rheumatoid Arthritis. Also in asthma drug level is maintained for night
to avoid bed time or early morning attacks.3
Approach for the manufacture of Controlled Release Dosage Form
The importances of controlled drug delivery systems that release bioactive
components over extended period of time have been recognized in pharmaceutical
field. Of many routes of drug delivery, oral administration is the most convenient
and commonly employed means for introduction of drugs to systemic circulation.
For oral delivery of drugs tablet formulation is effective. For tablet
formulation direct compression of blends of drugs and additives is the easy method
as direct compression technologies entails reduced labour, cost, time operational
space and equipment and further no heat or moisture is used so this is preferred
method for manufacture of controlled release dosage form.
One of the easy and convenient methods for fabrication of controlled release
dosage form is the incorporation of the drug in a matrix containing a hydrophilic,
rate controlling polymer e.g. (HPMC, XG) Drug release from such types of systems
is controlled by the hydration of polymer, which forms a gelatinous layer at the
surface of matrix, through which the included drug diffuses.
Water soluble drugs are released primarily by diffusion of dissolved drug
molecules across gel layer, while poorly water – soluble drugs are released
predominantly by erosion mechanisms13. The hydrophilic matrices show an initial
burst of drug release rate due to the release from the surface and the time needed for
the formation of an efficient gel layer capable of controlling water penetration and
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drug diffusion. This is the case of very soluble drugs and so zero-order release is not
obtained and this is the disadvantage of such system.
Materials used for Matrix System
The most widely used materials for matrix system include hydrophilic and
hydrophobic polymers. Commonly used hydrophilic polymers are Hydroxy propyl
methylcellulose (HPMC), Hydroxypropyl cellulose (HPC), xanthan gum (XG),(HE
C)Hydroxyethyl cellulose ,sodium alginate, poly (ethylene oxide) and cross linked
homo polymers and copolymers of acrylic acid. They are usually supplied in
micronized forms, as small particle size is critical for rapid gelatinous layer
formation on tablet surface.
HPMC is nonionic water soluble cellulose ether. It is available in four
different categories based on varying degrees of hydroxyl propyl and methyl
substitution namely E,F,J and K series. Xanthan gum is water soluble
polysaccharide gum. It is composed of D-glucosyl, D-mannosyl, and D-
glucosyluronic acid residues and differing proportions of o-acetyl and pyruvic acid
acetal. 5
Hydrophobic and monolithic polymer matrix systems usually of waxes and
water insoluble polymers. e.g. of waxes are carnauba wax, bees wax, candelilla wax,
paraffin wax, microcrystalline wax etc. e.g. of insoluble polymers: Eudragit RL 100,
RS 100, PO, ethyl cellulose, cellulose acetate, cellulose acetate butyrate etc.
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HYPERTENSION
Hypertension is defined as a increasing blood pressure 140/90 mmHg..
Hypertension is a risk factor for myocardial infarction, stroke, congestive heart
failure, end-stage renal disease, and peripheral vascular disease. The World Health
Organization reported that suboptimal blood pressure (SBP > 115 mmHg) is
responsible for 62% of all cerebrovascular diseases and 49% of all ischemic heart
diseases. In addition, suboptimal blood pressure is the number one cause of death
throughout the Western world.12
Clinical classification of hypertension
Although hypertension is rise in blood pressure above the normal clinical
values, which can be mild to malignant and therefore classified clinically as
summarized below.13
Table 1: Clinical classification of hypertension
Category Systolic(mm Hg) Diastolic(mm Hg)
Normal >130 <85
High Normal 130-139 85-89
Hypertension
Mild stage(stage1) 140-159 90-99
Moderate(stage2) 160-179 100-109
Severe(stage3) 180-209 110-119
Very sever(stage4) >210 >120
Malignant hypertension >200 >140
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Figure 3: Activation of renin angiotensin system is shown as follows
Sodium and water retention regulates blood volume and cardiac output.
Sodium concentration in the blood is regulated by the release of aldosterone,
reduction in glomerular filtration rate and release of atriopeptin hormone from atria
of heart.
Decreased   release   of   vasodepressor   agents   like   prostaglandins
counters   the vasopressor effect of Angiotensin – II.
Endocrinal   hypertension   is   due   to   a   number   of   endocrinal
diseases   like adreno cortical hyper function, hyperparathyroidism.
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Contraction of aorta causes systolic hypertension due to constriction and
diastolic hypertension results from changes in the circulation.
Neurogenic hypertension is due to disease like psychogenic, increase in
intracranial pressure.
Antihypertensive agents
Antihypertensive  agents  are  the  drugs  which  lower  the  blood  pressure
in hypertensive patients.
Classification of anti hypertensives
1. Diuretics
e.g. Chlorthalidone, Clopamide, Indapamide
2. β   Adrenergic blockers
e.g. Acebutolol, Atenolol, Metoprolol, Propranolol, Timolol
3. α Adrenergic blockers
e.g. Terazosin, Prazosin, Doxazosin
4. α + β Adrenergic blockers
e.g. Labetalol, Carvedilol
5. ACE inhibitors
e.g. Perindopril, Captopril, Enalapril, Lisinopril, Fosinopril,
trandolapril,  benazepril etc.
6. Calcium channel blockers
e.g. Amlodipine, Felodipine, Nifedipine, Nimodipine, Verapamil
7. Vasodilators
e.g. Hydralazine, Minoxidil, Sodium nitroprusside
8. Angiotension-II receptor antagonists
e.g. Candesartan, Losartan, Valsartan
9. Central sympatholytics
e.g. Clonidine, Methyldopa
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An overview on Perindopril Erbumine
Numerous studies demonstrated the efficacy of perindopril in the therapy of
essential hypertension.  Perindopril doses of 4 to 16 mg administered once daily are
more effective than placebo in the treatment of mild-to-moderate hypertension.
Doses greater than 8 mg offer no advantage in most patients; however, in some
patients doses of 12 or 16 mg daily provide greater therapeutic benefit. The
antihypertensive activity of perindopril is linear at doses up to 8 mg, with 2 mg
doses having only slight antihypertensive activity. Administration with
hydrochlorothiazide, indapamide, and nifedipine in patients demonstrating an
inadequate response to monotherapy has resulted in improved blood pressure
control.
The long-term efficacy of perindopril was reported in the results of an open
trial evaluating 690 patients.  Therapy was initiated with perindopril 4 mg once daily
and increased, if necessary, to 8 mg.  If diastolic blood pressure remained greater
than 90 mmHg on perindopril 8 mg, a diuretic was added, then another
antihypertensive agent was added if necessary.  After 1 year of therapy systolic and
diastolic blood pressure were reduced by 29 mmHg and 19 mmHg, respectively.
Perindopril monotherapy normalized blood pressure in 55% of the patients.  Blood
pressure control was achieved in 78% of the patients.  After 3 years, perindopril
monotherapy at 4 or 8 mg controlled blood pressure in 56% of the patients.13
The efficacy of perindopril was demonstrated in several studies enrolling
elderly patients with essential hypertension.  Perindopril doses of 2 to 8 mg daily
reduced systolic and diastolic blood pressure.  In a double-blind study enrolling 34
patients with a mean age of 84 years, perindopril reduced systolic pressure 10% and
diastolic pressure 9%. Blood pressure control (defined as blood pressure < 160/95
mmHg) was achieved in 92.5% of patients (62.5% at the dosage of 2 mg per day,
22.5% at 4 mg per day, 7.5% at 8 mg per day, and 5% at 8 mg per day plus 40 mg
nifedipine).  The efficacy of perindopril was evaluated in 2,927 elderly patients (>70
years) in an open study. At initiation of therapy with perindopril 2 or 4 mg once
daily, diastolic blood pressure was between 94 and 115 mmHg.  After 1 or 3 months
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of therapy, the dose could be doubled or a diuretic added if the perindopril dose had
reached 8 mg in patients with diastolic blood pressure remaining above 90 mmHg.
Diastolic blood pressure was reduced to less than 90 mmHg in 69% of patients at 1
month, 86% of patients at 3 months (in patients on perindopril alone), and 94% at 6
months.  At 6 months, diastolic blood pressure was lowered 28 mmHg and systolic
blood pressure 16.6 mmHg.
The efficacy of perindopril was demonstrated in several groups of patients
with hypertension and concomitant disease including hyperlipidemia, Type II
diabetes, ischemic heart disease, cardiac arrhythmia, peripheral arterial occlusive
disease, nephropathy with proteinuria, and chronic obstructive pulmonary disease.
Efficacy was demonstrated in patients with hypertension receiving nonsteroidal anti-
inflammatory agents (indomethacin or diclofenac).  In all groups, perindopril 4 mg
once daily effectively reduced blood pressure without negatively affecting the
patient's concomitant disease state or therapy.  Perindopril did not affect lipid or
apolipo protein levels in patients with hyperlipidemia, did not affect glucose control
in diabetic patients, had an anti-ischemic and anti anginal effect in those with
ischemic heart disease, and reduced urinary albumin excretion in patients with
proteinuria. Other studies have shown a lack of effect of perindopril on lipid or
carbohydrate metabolism. Several studies demonstrated the safety and efficacy of
perindopril in the treatment of hypertension in patients with diabetes or glucose
intolerance. Perindopril has not negatively affected glucose tolerance, insulin
sensitivity, renal function, or lipid profiles in diabetic patients treated long-term.14
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2. LITERATURE REVIEW
 Jignesh P. Prajapati et al., developed  absorption factor method and
validated for the simultaneous determination of perindopril erbumine and
amlodipine besylate in their combined pharmaceutical formulation dosage
form. Absorption factor method was performed for perindopril erbumine and
amlodipine besylate at wavelength maxima 216nm and 237nm respectively.
Result of analysis was validated by statistically. The result of the studies
showed that the proposed Spectroscopic method is simple, rapid, precise and
accurate.
 SB. Bhanja, P. Ellaiah et al., developed and optimized a sublingual tablet of
Perindopril which is an effective drug in the treatment of hypertension.
Perindopril containing tablets were prepared by direct compression method
using different ingredients such as Crospovidone, Sodium saccharin,
Mannitol, Microcrystalline cellulose, Talc and Magnesium stearate. The
tablets were evaluated for physical properties including Hardness, Weight
variation, Thickness, Friability, Drug content, Wetting time, Water
absorption ratio, In-vitro disintegration time, In-vitro dissolution study and
also Drug release kinetic study.
 Mukesh C. Gohel et al., fabricated modified release tablet of metoprolol
succinate using hydroxypropyl methylcellulose (HPMC) and xanthan gum as
a matrixing agent. The in vitro drug dissolution study was carried out in pH
6.8 phosphate buffer employing paddle rotated at 50 rpm. It was concluded
that the desired drug release pattern can be obtained by using a proper
combination of HPMC (high gelling ability) and xanthan gum (quick gelling
tendency). The matrix integrity during dissolution testing was maintained by
using hydroxyl propyl methylcellulose.
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 Murthy. P.N. V. N et al., prepared controlled-release matrix tablets of
Guaiphenesin and Salbutamol Sulphate and evaluated by using Na CMC,
Xanthan gum, HPMC100cps, Ethyl Cellulose (15cps), Compritol, Precirol in
different concentrations for treatment of respiratory disorders. The
manufacturing procedure was optimized with respect to the thickness
between 6.3 to 6.5mm, hardness 5 to 6 kg/cm2 and description being white,
oval shaped tablets with break line on one side. Formulation containing
NaCMC, Xanthan gum, HPMC100cps polymers showed higher rate of drug
release over a period of 24hrs.
 Masadi Rajukar et al., formulated the oral controlled release Trimtazidine
di hydrochloride tablets by using HPMC and Xanthan gum as rate
controlling polymer. The tablets were prepared by direct compression
method. Drug content in formulation was determined by UV Method. The
in vitro release study of matrix tablets were carried out in 0.1N Hydrochloric
acid with pH 1.2 for 10 hours. It was observed that the amount of polymer
influences the drug release.
 P. Subash Chandra Bose et al., described about the buccal region which
was attractive route for systemic drug delivery. Perindopril was an ACE
inhibitor widely used as an hypertensive agent shows less oral bioavailability
as it undergrows first pass metabolism. Perindopril patches were prepared
using HPMC K4M, Chitosin, HPMCP, PVP and PVA. In vitro release
studies were conducted for perindopril loaded patches in 6.6 pH phosphate
buffer solution. Buccoadhesive patches of perindopril can be developed as
potential controlled release formulation for the treatment of hypertension.
 Mridanga raj ray et al., have studied about the powders which were
evaluated for angle of repose, bulk density and tapped density whereas the
prepared tablets were evaluated for weight variation, thickness, diameter,
hardness, friability, drug content and in vitro release study.
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 Talukdar and Mooter et al.,have investigated the properties of xanthan
gum matrix tablet invivo. They have used poorly water soluble and highly
water soluble drugs for study. They have done single oral dose
pharmacokinetic study according to randomized crossover design in six
healthy male volunteers. There was no statistically significant difference in
time to reach the Cmax and AUC. But maximal plasma concentration was
varied considerably. They concluded that, although the common
pharmacokinetic parameters of the drug from test products were not
significantly different from the marketed product, the therapeutic efficacy of
drug from former may be superior to that of latter.
 Talukdar and RenaltKinget et al., have done the comparative study on
xanthan gum and HPMC as matrices for controlled release drug delivery.
They have concluded that drug diffusion in hydrated HPMC matrices is
higher than in hydrated xanthan gum matrices. This showed that xanthan
gum has higher ability than HPMC to retard the release of drug when used as
matrix forming agent.
 Kranz et al., studied the drug release mechanism from HPMC matrices and
developed a new model for quantitative predictions of controlled drug
delivery.
 Tao Yi et al., worked on controlled release for poorly soluble drug from
solid self-micro emulsifying formulations with high viscosity hydroxyl
propylmethylcellulose and they concluded that possibility of combining the
characteristics of controlled release and self-emulsifying formulations for the
biopharmaceutical requirements of oral poorly water-soluble drugs.
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 Ford and Velasco et al., studied the influence of drug (HPMC) (Hydroxy
methyl propyl cellulose) ratio and other technological factors such as drug
and polymer particle size and compression force on the drug release from the
matrices of HPMC. The influence was assessed by multi way analysis of
variance. They reported that release from HPMC ratio. The particle size also
influenced the release to lesser extent and the compression force didn’t affect
the release parameters.
 JamzadShahla et al., worked on development of a controlled release low
dose class II drug by using HPMC and they found that HPMC matrices
showed a significantly greater degree of hydration and swelling and stronger
texture property relative to PEO matrices. Results indicated that in the case
of low dose/low soluble drug, total drug release in a zero order manner
heavily depends on the synchronization of erosion and swelling fronts during
the entire dissolution study.
 VermaRajan K, Garg Sanjay et al., worked on selection of excipients for
extended release formulations of glipizide through drug–excipients
compatibility testing and they reported results of DSC along with IR and/or
HPLC were successfully employed to assess the compatibility of glipizide
with the excipients used in the development of extended release
formulations.
 Basak SC et al., prepared  propranolol  hydrochloride  matrix  tablets  with
hydroxypropyl methylcellulose polymer to control the release of drug with a
view to develop twice daily sustained release dosage form. The resulting
matrix tablets prepared with hydroxyl propyl  methyl cellulose K4M
fulfilled  all the official requirements of tablet dosage forms. The in vitro
drug release was measured in aqueous solutions for a total period of 12 h
using 1.2 pH bufferfor first 1 h and pH 7.5 buffer for the rest of period. The
drug release was within the limits of predetermined set USP requirements.
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 Kenneth I. Ozoemenaa et al., described about enantio selective,
potentiometric membrane electrodes based on carbon-paste impregnated
with and cyclodextrin as chiral selectors for the assay of S-perindopril is
described. Response characteristics showed that the proposed electrodes
could be reliably applied in the assay of S-perindopril raw material and its
pharmaceutical formulation. The best enantio selectivity and time-stability
were exhibited by cyclodextrin based electrodes.
 Yeole PG et al., made an attempt to increase therapeutic efficacy, reduce
frequency of administration, and improve patient compliance, by developing
sustained release matrix tablets of diclofenac sodium. Sustained release
matrix tablets of diclofenac sodium, were developed by using different drug:
polymer ratios, such as F1 (1:0.12), F2 (1:0.16), F3 (1:0.20), F4 (1:0.24) and
F5 (1:0.28). Xanthan gum was used as matrix former, and microcrystalline
cellulose as diluent. All the lubricated formulations were compressed using 8
mm flat faced punches. Compressed tablets were evaluated for uniformity of
weight, content of active ingredient, friability, hardness, thickness, in vitro
dissolution using basket method, and swelling index.
 NevinErk et al., developed a new sensitive, simple, rapid and precise
reversed-phase high performance liquid chromatographic (HPLC) and two
spectrophotometric methods to resolve binary mixture of Perindopril and
indapamide in the pharmaceutical dosage forms. The first method is based on
HPLC on a reversed-phase column using a mobile phase of phosphate buffer
pH 2.4 and acetonitrile (7:3 % v/v) was used. Linearity range for Perindopril
and indapamide was 5.0–70.0 and 8.0–35.0 g/ ml. In the second method, the
first derivative Spectrophotometry with a zero-crossing technique of
measurement is used for the simultaneous quantitative determination of
Perindopril and indapamide in binary mixtures without previous separation
step.
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 K S Lakshmi. et al.., validated HPTLC method for simultaneous
determination of losartan and perindopril in tablets. A simple, controlled and
precise high performance thin layer chromatographic method has been
developed for the simultaneous determination of losartan and perindopril in
tablet. Separation was carried out on pre-coated TLC plates, coated with
silica gel 60 F 254. The separation was done by using a mobile phase
toluene: acetonitrile: formic acid (5:5:0.3%v/v/v). After development, the
chromatographic plates were scanned at 215 nm. The Rf value of losartan
and perindopril was found to be 0.55 and 0.27 respectively. The results of the
analysis have been validated statistically and by recovery studies.
 Raja sekharanetal., was developed formulation and evaluation of
theophylline controlled released matrix tablets using antham gum. Controlled
release matrix tablets of theophylline were prepared with hydrophilic
polymer xantham gum and evaluated. Controlled release matrix tablets of
theophylline were prepared by wet granulation technique by varying polymer
ratios (1:1 and 1:2) and hardness (5,6 and 7 kg/cm2). IR spectroscopy
revealed that there was no interaction between the drug and the polymer used
in the formulation. In vitro dissolution studies were performed using Disso
2000 (Paddle type). From this study it was proved that the release of
theophylline from matrix tablets was influenced by both polymer ratio and
hardness.
 BhanjaSatyabrata et al., designed and carried out in vitro evaluation of
mucoadhesive buccal tablets of perindopril prepared by sintering technique
to avoid the first pass metabolism and to improve its bioavailability with
reduction in dose and also dose related side effects. The half-life of
perindopril is approximately 0.8 to 1 hrs. The tablets were prepared by direct
compression method containing polymer polyethylene oxide and carnauba
wax. The prepared tablets were sintered at various temperatures like 600 c
and 700c for 1.5 hr and 3 hr. The in vitro release of perindopril was
performed under sink conditions (phosphate buffer ph 6.8, at 37±0.50c and
50 rpm) using usp-xxiv dissolution apparatus.
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 Thawatchai Phaechamud et al.., formulated controlled release of
propranolol hcl from chitosan-lactose-xanthan gum matrix tablets. The
application  of  low  molecular  weight materials chitosan  as  matrix
component for controlled  propranolol HCL release  prepared by direct
compression was  studied. The  effect  of  the  additives  on  drug  release
from  matrix  tablets  containing  chitosan  was  investigated an incorporation
of  xanthan  gum  into chitosan tablet could prolong the drug release rather
than that containing single polymer.  The drug release could be modified by
addition of lactose. The drug release  was  gradually enhanced  as the  greater
amount  of  the  lactose  was  added  into  the matrix. Most of drug
dissolution profiles could  be  well fitted with first order kinetic release.
 Hisham E. Abdellatef et al., described about Simple, rapid, accurate and
sensitive spectrophotometric methods for the determination of perindopril.
The coloured products are measured spectrophotometrically at 588, 843, 419,
550 and 520nm for DDQ, TCNQ, TCNE, CL and p-CA, respectively,
optimization of different experimental conditions is described. Beer’s law is
obeyed in the range of 20–200mg/ml and colours were produced in non-
aqueous media and were stable for at least 1hr. Application of the suggested
methods to perindopril tablets are presented.
 J. Siepmanna et al., studied the modeling of drug release from delivery
systems based on HPMC.
 M.HarishShoaib et al., Evaluated drug release from ibuprofen matrix tablets
using HPMC.
 Antesh K jha et al., studied the formulation and in vitro evaluation of
sustained release matrix tablets of metoprolol succinate using hydrophilic
polymers.
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 Bishyajit Kumar biswas et al., studied the in vitro release kinetics study of
esomeprazole magnesium from methocel K15M and methocel K100M
matrix tablets.
 Roshanpradhan et al., studied the HPMC (HPMC- K4M, K15M and
K100M) matrix tablets containing indomethacin, the release character of
matrix tablets were investigated in the intestinal fluid 6.8 pH phosphate
buffer for 12 hours.
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3. AIM AND OBJECTIVE
The aim of the present work was to formulate and evaluate controlled release
matrix tablets of Perindopril Erbumine by using polymers like Xanthan gum, HPMC
K100 M.
Perindopril Erbumine is an anti hypertensive drug having low molecular
weight (368.46g/ml), short biological life (1.2hr), suggests it is an ideal candidate
for controlled drug delivery system which offers advantages like reduce frequency
of administration, better patient compliance and better controlled release profile.
Perindipril erbumine was effective in small doses (2 to 16 mg). Hence it was used in
hypertension and congestive cardiac failure.
Natural and synthetic polymers was designed for controlled release as they
are bio compatible, non toxic and better patient tolerance.
So, in present study planned to formulate Perindopril Erbumine as controlled
release matrix tablets formulation.
To study the effect of drug, polymer ratio in release rate.
To study the rate of drug release and mechanism of drug release from
designed formulation.
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4. PLAN OF WORK
The present study was proposed to carry out in the following phases for
formulation and evaluation of controlled release matrix tablets of Perindopril
Erbumine.
Phase-I
 Pre-formulation study of pure drug
 Compatibility study
 Fourier transform infrared spectroscopy (FT-IR)
 Preparation of standard curve of Perindopril Erbumine
 In acid buffer(pH 1.2)
 In phosphate buffer (pH 6.8)
Phase-II
Formulation and evaluation of controlled release matrix tablets of
Perindopril Erbumine
 Formulation of Perindopril Erbumine matrix tablets
 Evaluation of Perindopril Erbumine matrix tablets
 Physical evaluation
 Drug content study
 In vitro Dissolution study
 Kinetic data analysis
Phase-III
Accelerated stability studies.
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5. DRUG PROFILE
5.1 PERINDOPRIL ERBUMINE
Perindopril Erbumine is a dipeptide monoacid monoester with a
perhydroindole group and no sulphydryl radical; chemical name, tert-butyl
ammonium (2S, 3aS, 7aS)-1-(N-[(S)-1-ethoxycarbonyl butyl]-L-alanyl)
perhydroindole-2-carboxylate and used for the treatment of patients with
hypertension and symptomatic heart failure.
Physical and chemical properties
Empirical Formula : C
19 H32 N2 O5 ,C4 H11 N
Molecularweight : 368.46 g/mol
Meltingpoint : 126-128C
Category : Antihypertensive
Description : White crystalline powder, slightly hygroscopic
odourless, bitter in taste.
Solubility
The Perindopril erbumine is soluble in water, methanol, ethanol, acetic acid
and ethyl acetate, slightly soluble in ether, chloroform and benzene.
Chemical Nature
Perindopril erbumine dipeptide monoacid monoester with a per hydroindole
group and no sulphydryl radical.
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Structure
Structure of Perindopril Erbumine
Chemical name: Tert-butylammonium (2S, 3aS, 7aS)-1-(N-[(S)-1-ethoxycarbonyl
butyl]-L-alanyl) perhydroindole-2-carboxylate
Pharmacokinetics
Absorption                             : Well absorbed after oral administration.
Route of administration : Oral
Protien Binding : 10 - 20%
Bioavailability : 65% - 75 %
Metabolism : Hepatic
Half life : 1.2 hr
Excretion : Renal
Volume of Distribution : Approx. 140-160L/kg
Clearance : 219 – 362 m/min.
Dissociation Constant (Pka) : 2.6
Elimination Half-life                   : 0.8-1 hr
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Mechanism of Action
Perindopril erbumine inhibits ACE in human subjects and animals, while the
principle mechanism of perindopril is blood pressure reduction is believed to be
through the renin-angiotension- aldoserone system.
ACE inhibitors such as Perindopril cause lower blood pressure by inhibiting
angiotensin-converting enzyme (ACE), which is important for the formation of
angiotensin II. Perindopril inhibit the formation of angiotensin II from angiotensin
I. So, in blood decreases the levels of angiotensin II. Normally the Angiotensin II
would cause constriction of arteries and elevation of blood pressure so its inhibition
will relax the arteries and lower blood pressure, and improve the cardiac pumping
efficiency and output in patients with heart failure.
Adverse effects
Hypotension, tachycardia, chest pain, palpitations, hyperkalaemia,
skin rashes, non-productive cough, headache.
Contraindications
Diuretics reduce the bioavailability of perindopril erbumine, Pregnancy
contraindicated.
Interactions
Perindopril Erbumine is known to interact with other drugs like Fluorouracil,
Lithium, Phenobarbitone, Phenytoin (Na), Warfarin (Na), Digoxin, Azathioprine,
Aspirin. These interactions are sometimes beneficial and sometimes may pose
threats to life.
Indications
The drug is effective in the treatment of Hypotension, Anaphylactic reactions
during desensitization, membrane exposure, Intestinal angioedema, Neutropenia.
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Dosage
Adult dose: 4-8 mg as a single dose for 1 day.
Commercial dosage
Aceon 4mg (Solvey pharma.)
Conversyl 4mg ( Aurobindo Pharma)
Warnings / Precautions
Alcoholic drinks and alcohol containing medicines should be avoided during
Perindopril Erbumine treatment. Do not administer to subjects with a history of
blood dyscrasia.
Specification                          : 4mg
Storage : Protect from direct light.
Shelf life : 24 months.
Package
Tablets × 1 blister in PVC/aluminum blister packaging.
Chapter 5 Drug and Excipient Profile
Dept. of Pharmaceutics 40 J.K.K.Nattraja College of Pharmacy
5.2 EXCIPIENTS PROFILE
HYDROXY PROPYL METHYL CELLULOSE. (HPMC)20, 22
Synonyms: Cellulose, hydroxyl propyl methyl ether, HPMC, methocel, metolose
Chemical Formula: HPMC is a partially o-methylated and o-(2-hydroxy
propylated) cellulose. It is available in several grades, vary in viscosity and extent of
substitution
Structural Formula of HPMC K100M
Solubility
Soluble in cold water, forming a viscous colloidal solution, practically
insoluble in chloroform, ethanol, and ether, but soluble in mixture of ethanol and
dichloromethane, and mixture of methanol and dichloromethane
Molecular Weight        : 100 – 150000
Description
HPMC is an odorless and tasteless, white or creamy white colored fibrous or
granular powder
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Functional Category
Coating agent, film-former, stabilizing agent, suspending agent, tablet
binder, and viscosity increasing agent
Stability and Storage Conditions
HPMC is a stable material although it is hygroscopic after drying. Solutions
are stable between pH 3-11. Increasing temperature reduces the viscosity of
solutions. It undergoes a reversible sol to gel transformation upon heating and
cooling respectively. Stored in a well closed container, in a cool, dry place
Incompatibilities
It is incompatible with some oxidizing agent. Since it is nonionic, it will not
complex with metallic salts and ionic organics to form insoluble precipitates
Safety
It is generally regarded as a nontoxic and non-irritant material although
excessive oral consumption may have a laxative effect
Applications
HPMC is widely used in oral and topical pharmaceutical formulations. In
oral products it is primarily used as a tablet binder, film coating and as an extended
release tablet matrix. Concentration between 2-5% w/w may be used as a binder
either in wet or in dry granulation process. High viscosity grades may be used to
retard the release of water soluble drugs from a matrix. Lower viscosity grades are
used in aqueous film coating while higher viscosity grades are used with organic
solvents.
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XANTHAN GUM (21,22)
Chemical name : Xanthan gum
Empirical formula : (C35H49O29)n
Molecular weight : (933) n Daltons
Chemical Structure
Chemical Structure of Xanthan Gum
Xanthan is an anionic bacterial polysaccharide composed of a U-(1)-D-
Gle(1)-beta-D-GLC (cellulosic) backbone with a tri saccharide side chain linked
to C3 of every second glucose residue.
The side chain is U-D-Man-(1)-U-D-Gle A-1(/2)-6-O-acetyl-alpha-D-
Man-(1/beta-D-Glca-((12)-alpha-D with approximately 60% of the terminal
mannose units being pyruvylated and 90% of the proximal mannose units
substituted at C6 with O-acetyl groups. It has side chains of 2 mannose and 1
gluconic glucoronic acid group.
Xanthan gum is an exo cellular polysaccharide reduced by fermentation of
the bacteria Xantho monascam pestris.
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Description
Xanthan gum is off white granular powder. In cold water, it is dispersed to
form pseudo plastic mixtures. It is highly water soluble.
Melting point: 270 °C
Viscosity (dynamic):1200–1600 mPas (1200-1600 cP) for 1% w/v aqueous
solution at 25°C.
Salt solutions: Compatible and stable in solutions with high salt concentrations.
Others
It has unique enzyme resistance. Upon heating it may increase or maintain
viscosity. It is affected by shear but recovers hence, is thixotropic gelling agent. It
stabilizes solid, liquid, and gaseous dispersions, viscosity dispersions are highly
pseudoplastic, Xanthan exhibits pseudo plasticity on the basis of its helical structure.
Stability and Storage
Xanthan gum is a stable material Aqueous solutions are stable over a wide
pH range (pH 3–12), although they demonstrate maximum stability at pH 4–10 and
temperatures of 10–60°C. Xanthan gum solutions of less than 1% w/v concentration
may be adversely affected by higher than ambient temperatures: for example,
viscosity is reduced. Solutions are also stable in the presence of enzymes, salts,
acids, and bases.
Applications in pharmaceutical formulation or technology
Gum provides visibly clear solutions even at higher concentrations; it
exhibits less gummy mouth-feel than gums with more Newtonian characteristics.
Xanthan gum is commercially available in both clarified and non clarified forms.
Clarified Xanthan gives visibly clear solutions even at high concentrations, while
unclarified xanthan gums are opaque.  It acts as an emulsion stabilizer, holds water,
enhances freeze-thaw stability, inhibits starch retro gradation improves shelf-life
and serves to bring about stabilization dispersions, suspension, and emulsion, and
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thickeners. Although primarily used as a suspending agent, xanthan gum has also
been used to prepare sustained-release matrix tablets. Controlled-release tablets of
diltiazem hydrochloride prepared using xanthangum have been reported to sustain
the drug release in a predictable manner and the drug release profiles of these
tablets were not affected by pH and agitation rate.22
MAGNESIUM STEARATE (21, 23)
Synonym: Magnesium octadecanoate, octadecanoic acid, magnesium salt.
Chemical Name: Octadecanoic acid magnesium salt.
Empirical Formula: C36H70MgO4
Structural Formula
[CH3 (CH2)16COO] 2Mg
Structural Formula of Magnesium stearate
Molecular Weight
591.34
Melting Point
117-150 °C (commercial samples); 126-130 °C (high purity)
Solubility
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly
soluble in warm benzene and warm ethanol (95%).
CH3 O
-
O
CH3 O
-
O
Mg 2+
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Description
Magnesium stearate is a very fine, light, white, precipitated or milled,
impalpable powder of low bulk density, having a faint odour of stearic acid and a
characteristic taste. The powder is greasy to the touch and readily adheres to the
skin.
Typical Properties
Crystalline forms : High-purity magnesium stearate has been isolated
as a tri hydrate, a di hydrate, and an anhydrate.
Density (bulk) : 0.159 g/cm3
Density (tapped) : 0.286 g/cm3
Density (true) : 1.092 g/cm3
Flow ability : Poorly flowing, cohesive powder.
Melting range : 117–1500C (commercial samples)
Solubility : Practically insoluble in ethanol, ether and water;
slightly soluble in warm benzene and warm ethanol.
Specific surface area : 1.6–14.8 m2/g
Incompatibilities
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with
strong oxidizing materials. Magnesium stearate cannot be used in products
containing aspirin, some vitamins, and most alkaloidal salts.
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Applications in Pharmaceutical Formulation or Technology
Magnesium stearate is widely used in cosmetics, foods, and Pharmaceutical
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.
Functional Category
Tablet and capsule lubricant.
Stability and Storage Conditions
Magnesium stearate is stable and should be stored in a well closed container
in a cool, dry place.
Safety
Magnesium stearate is widely used as a pharmaceutical excipient and is
generally regarded as being non toxic following oral administration. However, oral
consumption of large quantities may produce a laxative effect or mucosal irritation.
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TALC (21, 23)
Synonyms
Hydrous magnesium calcium silicate, hydrous, magnesium silicate,
magnesium hydrogen meta silicate, powdered talc, Purtalc, soap stone, steatite.
Chemical Name
Talc
Structural Formula
Mg6 (Si2O5)4(OH) 4
Empirical Formula
Talc is a purified, hydrated, magnesium silicate, approximating to the
formula Mg6 (Si2O5)4(OH) 4. It may contain small, variable amounts of aluminum
silicate and iron.
Molecular Weight
379.27 g
Solubility
Talc is practically insoluble in dilute acids and alkalis, organic solvents, and
water.
Description
Talc is a very fine, white to greyish-white, odourless, impalpable, unctuous,
crystalline powder. It adheres readily to the skin and is soft to the touch and free
from grittiness.
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Typical Properties
Moisture content : Talc absorbs insignificant amounts of water at
2580C and relative humidity’s up to about 90%.
Particle size distribution : Varies with the source and grade of material.
Refractive index : nD20 = 1.54–1.59
Solubility : Practically insoluble in dilute acids and alkalis,
organic solvents, and water.
Specific gravity : 2.7–2.8
Specific surface area : 2.41–2.42m2/g
Storage Conditions : Talc should be stored in a well-closed
container in a cool, dry place.
Incompatibilities : Incompatible with quaternary ammonium
compounds.
Applications in Pharmaceutical Formulation or Technology
Talc is used in oral solid dosage formulations as a glidant and lubricant (1-
10%) and diluent (5-30%), as a dissolution retardant in the development of
controlled-release products, as an adsorbent, as a dusting powder in topical
preparations (90-99%).
Functional Category
It is used as an anti caking agent, glidant, tablet and capsule diluent, tablet
and capsule lubricant.
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Storage Conditions
Talc should be stored in a well-closed container in a cool, dry place.
Safety
Talc is not absorbed systemically following oral ingestion and is therefore
regarded as an essentially non-toxic material. However, intranasal or intravenous
abuse of products containing talc can cause granulomas in body tissues, particularly
the lungs.
POLYVINYL PYRROLIDONE (20, 21)
Synonym
Povidone, polyvinyl pyrrolidone, PVP, kollidone, and plasdone
Chemical formula
1-ethenyl-2-pyrrolidinone homopolymer. (C6H9NO) n
Molecular weight
2500-3000000
Description
It is white to creamy white, odourless or almost odourless, hygroscopic
powder
Functional category
Tablet binder, suspending or viscosity increasing agent
Solubility
Readily soluble in water, organic solvents including monohydric (ethanol,
methanol) and polyhydric alcohols, acids, esters, ketones, and chloroform
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Stability and storage conditions
Aqueous solutions are susceptible to growth of molds and consequently
required the addition of suitable preservatives.
Incompatibility
It forms molecular adducts in solution with sulfathiazole, sodium salicylate,
salicylic acid, phenobarbital, tannin, and other compounds
Safety
Chemically, PVP is inert and nontoxic. It does not irritate the mucous
membrane of rabbit eyes, antigenic property and does not interfere in antibody
formation studies.
Applications
Carrier for drug, dispensing agent, suspending or viscosity builder, tablet
binder, tablet diluents and coating agent.
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MICRO CRYSTALLINE CELLULOSE
Synonym
Avicel PH; Cellets; Celex; Hellulosum micro cristallinum, MCC Sanaq.
Molecular weight :      36000
Empirical formula :      C6H10O5
Functional category
Adsorbent, suspending agent, tablet and capsule diluent, tablet disintegrant.
Solubility
Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble
in water, dilute acids and most organic solvents.
Stability and storage conditions
Microcrystalline cellulose is a stable though hygroscopic material. The bulk
material should be stored in a well closed container in a cool place and dry place.
Incompatibilities
Microcrystalline cellulose is incompatible with strong oxidizing agents.
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6. MATERIALS AND METHODS
6.1.1 LIST OF MATERIALS
List of materials and equipments were used for the formulation and
evaluation given in table no 2 and 3
Table no 2: materials and their suppliers
S. No. Materials Source
1. Perindopril Erbumine AurobindoPharma Limited, Hyd
2. Xanthan gum S.d. Fine chemicals limited, Mumbai
3. HPMCK100M S.d. Fine chemicals Chemicals, Mumbai
4. MCC S.d. Fine chemicals limited, Mumbai
5. PVP S.d. Fine chemicals limited, Mumbai
6. Talc S.d. Fine chemicals limited, Mumbai
7. Magnesium stearate S.d. Fine chemicals limited, Mumbai
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6.1.2 LIST OF EQUIPMENTS
Table 3: Equipments and their Manufacturer
S. No Name of the Equipment Supplier / Manufacturer
1. Electronic balance Shimadzu BL-2204
2. Hot air oven Spencers
3. Tablet compression machine Kimya engineers
4.
Tablet Dissolution tester USP
XXII
Lab India
5. Disintegration apparatus Campbell electronics, Mumbai.
6. Friability test apparatus Roche Friabilator.
7. pH meter Systronics, Mumbai.
8.
UV-Visible
Spectrophotometer
Lab India 3000.
9. Hardness tester Monsanto
10. Blender tester Konark instruments.Ambala,Haryana.
11. Rotary Shaker Konark instruments.Ambala,Haryana.
12. FTIR Spectrophotometer Bruker Alpha.
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6.2 PRE-FORMULATION STUDIES
Pre-formulation may be described as a phase of the research and
development process where the formulation scientist characterizes the physical,
chemical and mechanical properties of new drug substances, in order to develop
stable, safe and effective dosage forms. Ideally the pre-formulation phase begins
early in the discovery process such the appropriate physical, chemical data is
available to aid the selection of new chemical entities that enter the development
process during this evaluation possible interaction with various inert ingredients
intended for use in final dosage form are also considered in the present study.
The following pre-formulation studies were performed
 Study of organoleptic properties
 Solubility analysis
 Melting point of drug
 Drug powder characterization
 Drug-excipients compatibility study by FT-IR24
6.2.1 Organoleptic properties
The Organoleptic character of the drug like colour, odour, taste and
appearance play an important role in the identification of the sample and hence they
should be recorded in an descriptive terminology.
6.2.2 Solubility studies
It is important to know about solubility characteristics of a drug in aqueous
systems, since they must possess some limited aqueous solubility to elicit a
therapeutic response. Quantitative determination of solubility was made by
preparing saturated solution of drug in a constant volume of water, methanol,
ethanol, acetic acid and ethyl acetate and resulting solutions were kept at room
temperature for 24 hours with intermediate shaking.
Chapter 6                                                                              Materials and methods
Dept. of Pharmaceutics 55 J.K.K.Nattraja College of Pharmacy
6.2.3 Melting point
The melting point of Perindopril Erbumine was determined by capillary
method. The small quantity of Perindopril Erbumine was placed in apparatus and the
melting point was determined which was matched with standards.
6.2.4 Loss on drying
Determination was done on 1.000 g of sample by drying it in an oven at
100°C to 105°C for 3 hours.
Accurately weighed the substance to be tested.  If the sample was in the form
of large crystals, reduced the particle size to about 2 mm by quickly crushing. A
glass stopper, shallow weighing bottle that had been dried for 30 minutes under the
same conditions to be employed in the determination were taken.  The sample was
taken in bottle and replaced with the cover. The bottle with the contents was
accurately weighed. The sample was evenly distributed practicable to a depth of
about 5 mm by gentle  and sidewise shaking. The loaded bottle was placed in the
drying chamber. The sample was dried at the specified temperature until a constant
weight was reached. Upon opening the chamber, the bottle was closed promptly and
allowed to come to room temperature in desiccators before weighing.
The difference between successive weights should not be more than 0.5mg.
The loss on drying was calculated by the formula
(W2-W3)
% LOD = ----------------------------- X 100
(W2-W1)
Where, W1 = Weight of empty weighed bottle
W2 = Weight of weighed bottle + sample
W3 = Weight of weighed bottle + dried sample
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6.2.5 Drug powder characterization25
6.2.5.1 Angle of repose
Angle of repose is the maximum angle of a stable slope determined by
friction, cohesion and the shapes of the particles. The internal angle between the
surface of the pile and horizontal surface is known as the angle of repose and is
related to the density, surface area and co-efficient of friction of the raw material.
Method
Angle of repose was determined by using funnel method. The height of the
funnel was adjusted in such a way that the tip of the funnel just touches the heap of
the blends. Accurately weighed blend was allowed to pass through the funnel freely
on the surface. The height and diameter of the powder cone was measured and angle
of repose was calculated using the following equation.
Ө = tan-1 (h/r)
Where, h = height of heap, r = radius of heap, Ө = angle of repose.
Table 4: Angle of repose limits
Angle of repose Flow property
<25o Excellent
25-30 o Good
30-40 o Passable
>40 o Very poor
6.2.5.2 Bulk density
Bulk density is defined as the mass of the powder divided by the bulk
volume. Bulk density largely depends on particle shape as the particle become more
spherical in shape, bulk density increase. In addition as the granule size increases
bulk density decreases.
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It is the ratio between a given mass of a powder and it’s bulk volume
Bulk Density = Bulk Mass / Bulk Volume
Method
A given quantity of the power was transferred to a measuring cylinder and
tapped mechanically either manually or using some tapping device till a constant
volume is obtained. This volume is the bulk volume (v) and it includes the true
volume of the powder and the void space among the powder particles. A given peak
of powder has air spaces between the particles .This air space called void space or
void volume.
6.2.5.3 Tapped density
It is the ratio of total mass of the powder to the tapped volume of powder.
The volume was measured by tapping the powder. Then the tapping was done and
the tapped volume was noted. The tapped density was calculated by using the
following formulae
Tapped Density =
Vf
m
Where, m = initial weight of material in gm,
Vf = volume of material after tapping.
6.2.5.4 Measurement of powder compressibility26
The compressibility Index and Hausner’s ratio are measures of the
propensity of a powder to be compressed. As such, they are measures of the relative
importance of inter particulate interactions. In a free flowing powder, bulk density
and tapped density have closer values as such interactions are generally less. For
poorer flowing materials, there are frequently greater inter particle interactions and
hence, a greater difference between bulk and tapped densities was observed. These
differences are reflected in the compressibility Index and the Hausner’s ratio
calculated by the formula
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Compressibility index: =
0
0 )(100
V
VfV 
Where,
Vf = final tapped volume,
V0 = initial untapped volume.
Table 5: Limits of Compressibility index
S.no Compressibility index Flow
1 5-12 Free flow
2 12-16 Good flow
3 18-21 Fair
4 23-25 Poor
5 33-38 Very poor
6 >40 Extremely poor
Hausner’s ratio =
Vf
V0
Where, Vf = final tapped volume, Vo = initial un tapped volume.
Table 6: Limits of Hausner’s ratio
S. no Hausner’s ratio Flow
1 1-1.2 Free flowing
2 1.2-1.6 Cohesive powder
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6.3 Drug-Excipient Compatability Studies
Fourier Transform Infrared (FTIR) Spectroscopy
FT-IR spectra of pure drug, Pure HPMC K100 M, Pure Xanthan Gum &
physical mixtures of this polymer with drug were recorded on Bruker alphaFT-IR
spectrophotometer using KBr discs. The instrument was operated under dry air
purge and the scans were collected at scanning speed 2 mm/sec with resolution of 4
cm-1 over the region 4000-400 cm-1. The scans were evaluated for presence of
principle peaks of drug, shifting and masking of drug peaks and appearance of new
peaks due to polymer interaction.
6.4 Construction of calibration curve
6.4.1 Calibrations curve of Perindopril Erbumine in Acid buffer pH 1.2
Preparation of 0.2 M potassium chloride
0.2 M Potassium Chloride was prepared according to IP 1996. A quantity of
14.9 gm of potassium chloride was dissolved in water and made up the volume to
1000 ml using water.
Preparation of 0.2M HCl
0.2 M HCl prepared by diluting 17ml of Conc. HCl in to water and made up
the volume to 1000ml using water.
Preparation of Acid buffer pH 1.2
The Acid buffer pH 1.2 prepared according to IP 1996 by mixing the 50ml of
0.2 M potassium chloride and 85 ml of 0.2 M HCl and made up the volume to
200ml using water.
Scanning of Perindopril Erbumine in Acid buffer pH 1.2
The absorption maxima of the standard solution were scanned between 200-
400 nm on Lab India 3000 UV-Vissible spectrophotometer. The absorption maxima
were found at 216 nm.
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Procedure
An accurately weighed quantity of Perindopril Erbumine was dissolved in
an amount of methanol not exceeding 2% of final volume and diluted quantitatively
with Acid buffer pH 1.2 to obtain a solution having known concentration(4, 8, 12,
16, 20, 24, 28 and 32 µg/ml). Absorbance of Perindopril Erbumine determined at
216 nm.
6.4.2 Calibration curve of Perindopril Erbumine in phosphate buffer pH 6.8
Preparation of 0.2 M potassium dihydrogen phosphate
0.2 M potassium dihydrogen phosphate was prepared according to IP 1996.
A quantity of 27.2 grams of potassium dihydrogen phosphate was dissolved in water
and made up the volume to 1000ml using water.
Preparation of 0.2 M NaOH
0.2 M NaOH prepared by dissolving 8 gms of NaOH in to water and made
up the volume to 1000ml using water.
Preparation of phosphate buffer pH 6.8
The phosphate buffer pH 6.4 prepared according to IP 1996 by mixing the
50ml of 0.2 M potassium dihydrogen phosphate and 39.1ml of 0.2 M NaOH and
make up the volume to 200ml using water.
Scanning of Perindopril Erbumine in phosphate buffer pH 6.8
The absorption maxima of the standard solution were scanned between 200-
400 nm on Lab India 3000 UV-Vissible spectrophotometer. The absorption maxima
were found to 216 nm.
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Procedure
An accurately weighed quantity of Perindopril Erbumine was dissolved in
phosphate buffer pH 6.8 to obtain a solution having known concentration (4, 8, 12,
16, 20, 24, 28 and 32 µg/ml). Then absorbance of Perindopril Erbumine was
determined at 216 nm.
6.5 Formulation of controlled release matrix tablets of Perindopril
Erbumine by direct compression method
The key ingredients included in the formulation are
Hydrophilic polymers: Xanthan gum  and HPMC K100M
Filler : MCC
Anti adherent : Talc
Lubricant : Magnesium Stearate
Binder                         : PVP
Accurately weighed quantities of polymer and MCC were taken in a mortar
and mixed geometrically to this required quantity of Perindopril Erbumine was
added and mixed with the help of pestle. The powder blend was then lubricated with
magnesium stearate and talc mixed for about 3 minutes.
Compression operation was carried on rotary tablet compression machine
fitted with 6 mm round shaped, standard flat face punch sets having plain on both
sides at average weight 100 mg/tab.
Before going to compression powder blend was evaluated for all physical
parameters like angle of repose, bulk density, tapped density, carr’s index, hausner‘s
ratio.
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Formula of Controlled release matrix tablets of Perindopril Erbumine
Table 7: Formulation of Perindopril Erbumine controlled release matrix tablet
Ingredients
(mg)
F1 F2 F3 F4 F5 F6 F7 F8 F9
Perindopril
Erbumine
4 4 4 4 4 4 4 4 4
HPMC
K100M
30 35 40 - - - 15 20 20
Xanthan
gum
- - - 30 35 40 20 15 20
PVP 5 5 5 5 5 5 5 5 5
MCC 59 54 49 59 54 49 54 54 49
Talc 1 1 1 1 1 1 1 1 1
Mg. stearate 1 1 1 1 1 1 1 1 1
Total wt(mg) 100 100 100 100 100 100 100 100 100
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6.6 Evaluation of controlled release tablets of Perindopril Erbumine
6.6.1 Tablet thickness and diameter
Thickness and diameter of tablets were important for uniformity of
tablet size. Thickness and diameter were measured using vernier callipers.
6.6.2 Hardness
This test is used to check the hardness of a tablet which may undergo
chipping or breakage during storage, transportation and handling. In this six
tablets were selected at random and the hardness of each tablet is measured with
Monsanto hardness tester. The hardness is usually measured in terms of kg/cm2.
6.6.3 Friability
The friability test was carried out to evaluate the hardness and stability
instantly in Roche Friabilator. Here twenty tablets were weighed (Wo) initially
and put in a tumbling and rotating apparatus drum. Then, they are subjected to
fall from 6 inches height. After completion of 100 rotations i.e., 25 rpm for 4
minutes, the tablets were again weighed (w). The percent loss in weight or
friability (F) is calculated by the formula
F= (1-W/Wo) x 100
F= friability
Wo= initial weight
6.6.4 Weight variation
This test is performed to maintain the uniformity of weight of each
tablet which should be in the prescribed range. This was done by sampling
randomly and weighing 20 tablets and average weight was calculated. Not more
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than two of the individual weights deviate from the average weight by more
than the percentage show in the table 8 and none deviate by more than twice the
percentage The mean and standard deviation were determined.
Table 8: Pharmacopoeial specifications for tablet weight variation
Average
weight of
tablets (mg)
(I.P)
Average weight
of tablets   (mg)
(U.S.P)
± %
deviation
allowed
Less than 80 Less than 130 10
80 – 250 130 – 323 7.5
More than 250 More than 324 5
6.6.5 Content uniformity
This test was performed to maintain the uniformity of weight of active
ingredient in each tablet which should be in the prescribed range according to
the Indian Pharmacopoeia. This test was performed by taking twenty tablets
randomly, weighed and powdered. A quantity of powdered tablet equal to 100
mg of perindopril Erbumine is dissolved in 0.1 N HCL in 100ml volumetric
flask. It is diluted and the absorbance is measured at 224 nm using 0.1 N HCL
as blank and the % drug content was estimated using the following formula.
Absorbance-intercept
Concentration (mcg/ ml) = -------------------------------
Slope
Drug content (mg) = concentration x dilution factor
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Drug content (mg)
% Drug content = -------------------------- x 100
Label claim (mg)
6.6.6 In vitro dissolution studies
Dissolution studies were carried out by using USP II dissolution
apparatus. The stirring speed was 50 rpm. It was maintained at 37 ± 1˚C.
Samples of 5ml were withdrawn at predetermined time intervals, filtered and
replaced with 5ml of fresh dissolution medium. The collected samples were
suitably diluted with dissolution fluid wherever necessary and were analyzed  at
216 nm by using a double beam UV spectrophotometer. Each dissolution study
is performed three times and the mean values were taken.
Details of dissolution test
Dissolution test apparatus : USP TYPE II
Speed : 50 rpm
Stirrer : Paddle type
Volume of medium : 900 ml
Aliquot taken at each time interval : 5 ml
Medium used : pH 1.2 acid buffer for 2 hrs. And
pH 6.8 phosphate buffer for 22 hr
Temperature : 37 ± 0.5 0C
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6.7 Release kinetic study
The rate and mechanism of release of Perindopril Erbumine through the
prepared controlled release matrix tablets were analyzed by fitting the drug release
data into
Zero order equation
Q = Q0 – K0 t
In this equation Q is the amount of drug remaining undissolved at time t, Q0
is the amount of drug undissolved at t = 0 and K0 is the corresponding release rate
constant.
First order release equation
ln Q = ln Q0 – K1t
Where M is the amount of drug undissolved at time t, Q0 is the amount of
drug undissolved at t = 0 and K1 is the corresponding release rate constant.
Higuchi Square Root Law equation
Q = K2t0.5
Where Q (Q = 100 - M) is the amount of drug dissolved at time t and K2 is
the diffusion
The Korsmeyer - peppas equation
Mt / M ∞ = K tn
Where Mt / M∞ is the fraction of drug released at time t, K is the Korsmeyer
release rate constant and n characterizes the mechanism of drug release from
formulations during diffusion process. If n = 0.45 it is case I or Fickian diffusion,
0.45, n, 0.89 is for anomalous diffusion or non- Fickian transport, n = 0.89 for case
II transport, n .0.89 for super case II transport.
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From Korsemeyerspeppas model,
 The value of n falls between 0.5 to 1 (0.5 < n <1) indicating non-fickian release.
 The value of n =0.5 indicating Fickian diffusion i.e. first order release
 The value of n = 1, indicating the Zero order release or case 2 transport
 The value of n >1, indicating the Super case 2 transport
6.8 Stability protocol
The purpose of stability testing is to provide evidence on how the quality of a
drug substances or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light and to establish a re-
testing for the drug substances or a shelf-life for the drug product and recommended
storage conditions.
The storage conditions used for stability studies were accelerated conditions
(40°C±2°C/75%±5% RH). Stability study was carried out for the optimized
formulation. Tablets of optimized formulation were packed in strips and kept in
stability chamber for 3 months on above mention temperature.
The samples were kept at 40°C±2°C/75%±5% RH and analysed for weight
variation, hardness, friability, drug content and in vitro dissolution study for every
month for a period of 3 months.
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7. RESULTS AND DISCUSSION
7.1 PRE-FORMULATION STUDIES
7.1.1 Appearance
The sample of Perindopril Erbumine was white or almost white, odourless or
almost odourless crystalline powder.
7.1.2 Solubility
The Perindopril Erbumine was soluble in water, methanol, ethanol, acetic
acid and ethyl acetate, very slightly soluble in ether, chloroform and benzene.
7.1.3 Melting point
The melting point was found to be 126-128C.
7.1.4 Physical characteristics of drug
Table No 12: Physical characteristics of drug (Perindopril Erbumine)
S. No Parameter Specifications
1 Loss on Drying (%) 0.40
2 Bulk density (g/ml) 0.415
3 Tapped Density (g/ml) 0.498
4 Hausner’s  ratio 1.26
4 Compressibility index (%) <15
5 Angle of repose ( ’) 24.11º
All the powder characteristics were good and satisfied according to
pharmacopeia.
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7.2   FTIR Studies
Potential chemical interactions between the drug and polymer may change the
therapeutic efficacy of the drug. To investigate the possibilities of chemical
interaction between drug and excipients. FTIR spectra of pure drug and optimized
formulations were analyzed over the range 400-4000cm-1. Compatibility studies
were performed using FT-IR Spectrophotometer. The FT-IR spectrum of pure
Perindopril Erbumine drug was compared with FT-IR spectrum of physical mixture
of Perindopril Erbumine (Perindopril Erbumine, HPMC K100 M, Xanthan gum,
MCC, PVP, Talc and Mg.sterate). The spectra for all formulations are shown below
figure no 4 to 9.
Figure No 4: FTIR spectra of Perindopril Erbumine
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Figure No 5: FTIR spectra of Xanthan gum
Figure No 6: FTIR spectra of HPMC
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Figure No 7: FTIR spectra of Magnesium stearate
Figure No 8:  FTIR spectra of MCC
Wave number (cm-1)
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Figure No 9: FTIR spectra of Talc
Wave number (cm-1)
Figure No 10: FTIR spectra of Drug with excipients
Chapter 7 Results and Discussion
Dept. of Pharmaceutics 73 J.K.K.Nattraja College of Pharmacy
Table No 10: FT-IR Peaks of various compounds
Wave number
in cm-1
Functional
groups
Pure drug
perindopril
erbumine
Physical
mixture
1210-1150 C-N Stretching 1151.2 cm-1 1152.4 cm-1
1360-1180 C-NH2 Stretching 1306.1 cm-1 1307.5 cm-1
1900-1600 C=O Stretching 1800.8 cm-1 1800.8 cm-1
2990-2850 C-CH3 Stretching 2984.9 cm-1 2983.2 cm-1
3490-3300 N-H Stretching 3305.9 cm-1 3306.7 cm-1
The FTIR spectrum analysis showed that there is no appearance or
disappearance of any characteristic peaks of pure perindopril erbumine and in the
physical mixture of drug with polymer and excipients. The presence of peaks at the
expected range confirms that the materials taken for the study are genuine. The
results were showed in table no 10.
Due to stretching C-N, C-NH2, C=O, C-CH3 and N-H respectively in
optimized formulations also these peaks were well preserved with additional peaks
which correspond to the excipients used in the formulation. This indicated that no
drug excipients interaction.
7.3 Calibration curve of Perindopril Erbumine
Calibration curve of Perindopril Erbumine was determined in pH 1.2 acid
buffer, by plotting absorbance versus concentration (µg/ml) at 216 nm and by using
concentration at range of 4-32 µg/ml and the following result was obtained.
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A. In pH 1.2 Acid buffers
The calibration curve of the Perindopril erbumine was prepared by using pH
1.2 acid buffer.
Table No 11: Data for calibration curve of Perindopril erbumine in Acid
buffer pH 1.2
S. No. Concentration (µg/ml) Absorbance
1 0 0
2 4 0.10458
3 8 0.18481
4 12 0.25583
5 16 0.36112
6 20 0.44562
7 24 0.52758
8 28 0.62594
9 32 0.69025
Figure No 11:Calibration curve Graph in pH 1.2 Acid Buffer
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B. In pH 6.8 Phosphate Buffer
The calibration curve of the Perindopril erbumine was prepared in the
Phosphate buffer pH 6.8.
Table No 12: Data for calibration curve of Perindopril erbumine in phosphate
buffer pH 6.8
S.NO. Concentration(µg/ml) Absorbance
1 0 0
2 4 0.07442
3 8 0.15916
4 12 0.24156
5 16 0.30596
6 20 0.36892
7 24 0.45565
8 28 0.53568
9 32 0.56364
Figure No 12: Calibration curve Graph in PH 6.8 Phoshphate  Buffer.
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7.4 Evaluation of pre compression parameters
Table No 13: Powder characterization of formulations
Formulation
code
Angle of
repose
(± SD)
BD
(gm/ml)
(± SD)
TD
(gm/ml)
(± SD)
Carr’s
index (%)
(± SD)
Hausner’s
ratio
(± SD)
F1 23.03±0.04 0.412±0.02 0.477±0.02 14.92±0.05 1.18±0.05
F2 20.85±0.01 0.407±0.03 0.486±0.01 14.91±0.07 1.19±0.04
F3 20.85±0.04 0.410±0.06 0.481±0.01 13.93±0.04 1.21±0.02
F4 22.30±0.07 0.398±0.04 0.491±0.07 14.72±0.01 1.19±0.06
F5 19.98±0.09 0.396±0.03 0.480±0.03 13.12±0.03 1.16±0.03
F6 22.06±0.06 0.412±0.01 0.489±0.01 14.27±0.01 1.15±0.01
F7 23.19±0.03 0.409±0.04 0.472±0.02 13.56±0.04 1.16±0.03
F8 22.05±0.09 0.401±0.05 0.492±0.03 12.91±0.07 1.17±0.05
F9 24.11±0.03 0.415±0.01 0.498±0.04 15.00±0.06 1.26±0.04
(n=3±S.D) (S.D=Standard deviation)
For the powder blend of all the formulated batches, the angle of repose was
found to be in the range of 19° to 24°, thus indicating that the flow properties were
excellent. Hausner’s ratio was less than 1.20 for all the batches indicating good flow
properties.
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7.5 Evaluation of Perindopril Erbumine tablets
The results were showed in table no 14.
Table No 14: Evaluation of Physical Characteristics of controlled release
matrix tablets of Perindopril Erbumine
(n=3±S.D) (S.D=Standard deviation)
The histograms of hardness, thickness, weight variation, friability and drug
content was mentioned in figure no 13 to 16.
Formul
ation
code
Weight
variation(
mg)
(±SD)
Hardness
(kg/cm2)
(±SD)
Thickness
(mm)
(± SD)
Drug
content
( mg)
(± SD
Friability
%
F1 100.4±1.24 4.93±0.23 3.009±0.02 93.76±0.19 0.30
F2 100.9±1.61 4.13±0.30 3.009±0.02 98.16±0.27 0.40
F3 100.4±1.56 3.73±0.11 3.008±0.02 89.87±0.41 0.16
F4 100.3±1.28 3.93±0.23 3.009±0.02 97.28±0.33 0.40
F5 100.8±1.16 4.13±0.15 3.008±0.02 93.48±0.26 0.60
F6 100.0±1.42 4.4±0.2 3.010±0.0 95.67±0.17 0.60
F7 100.8±1.00 4.0±0.2 3.009±0.02 93.87±0.32 0.50
F8 100.8±1.28 3.53±0.11 3.009±0.02 88.92±0.21 0.51
F9 100.3±1.04 4.0±0.115 3.009±0.02 97.87±0.16 0.57
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Figure No 13: Thickness and Hardness of Perindopril Erbumine tablets
Figure No 14: Friability of Perindopril Erbumine tablets
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Figure No 15: Weight variation of Perindopril Erbumine tablets
Figure No 16: % Drug Content of Perindopril Erbumine tablets
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 The weight variations for all the formulation F1 to F9 were within the
pharmacopoeial specification.
 Thickness of all the formulations F1 to F9 was in the range of 3.008-3.010
mm.
 Hardness of all the formulations F1 to F9 was in the range of 3.53- 4.13
kg/cm2.
 Diameter of all the formulations F1 to F9 was in the range of 6.008-6.010
mm.
 Friability of all the formulations F1 to F9 was in the range of  0.16%  to
0.60%
 Drug content all the formulations F1 to F9 was in the range of 93 to 100%.
All the prepared formulations were tested for physical parameters like
Hardness, Thickness, Weight variation, Friability, were found to be within
pharmacopoeial limits. The drug content of all the formulations was determined and
was found to be within the permissible limit. This study indicated that prepared
formulations were good.
7.6 INVITRO DRUG RELEASE STUDY
The dissolution studies of the formulation (F 1 to F9) were carried out in USP
dissolution apparatus (paddle) in 900 ml of 0.1N HCL of pH 1.2 for 2 hr and
phosphate buffer pH 6.8 for remained 22 hr as dissolution medium. The reports are
represented in the tables no 15 to 17 and Fig 17 to 19 respectively. The results of
dissolution study was depends on polymer concentration.
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Table No 15: Cumulative Percentage drug release of formulations with
HPMC K100M (F1-F3)
Time(hr) Cumulative
% drug release
F1
Cumulative
% drug release
F2
Cumulative
% drug release
F3
0 0 0 0
1 4.98 3.64 3.15
2 7.86 6.99 6.42
4 15.46 13.98 12.87
6 24.19 22.89 19.65
8 36.47 33.75 31.16
10 49.19 47.39 42.41
12 60.46 57.97 52.65
14 74.49 70.38 65.11
16 83.78 79.13 74.42
18 90.19 86.72 82.21
20 96.74 91.31 86.41
22 99.24 94.74 89.63
24 - 97.27 90.81
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Figure No 17: Cumulative percentage drug release of formulations containing
HPMC K100 M
From the above figure no 17 it can be observed that the polymer HPMC
K100 M has controlled effect on the release of drug from the controlled release
matrix tablet. The percentage of drug release from formulations F1, F2 and F3 were
99.24%, 97.27% and 90.81% respectively and difference in the drug release profile
of various formulations was due to the presences of different concentrations of
polymer. The cumulative percent of drug release from various formulations and
release coefficients values of the various models for respective formulation were
represented in table no 15.
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Table No 16: Cumulative Percentage drug release of formulations with
Xanthan gum (F4-F6)
Time(hr) Cumulative
% drug
release F4
Cumulative
% drug release
F5
Cumulative
% drug release
F6
0 0 0 0
1 3.99 3.74 3.35
2 10.31 9.45 8.12
4 19.15 17.34 16.69
6 28.76 27.68 25.42
8 39.35 36.93 34.25
10 51.59 47.41 43.85
12 63.79 58.79 54.56
14 75.59 70.63 65.42
16 84.65 80.72 75.14
18 92.41 87.52 82.24
20 97.19 92.74 87.28
22 99.98 96.27 90.71
24 - 98.15 92.64
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Figure No 18: Cumulative  percentage  drug release of formulations containing
Xanthan gum (F4-F6)
From the above figure no 21 it can be observed that the polymer xanthan
gum has controlled effect on the release of drug from the controlled release matrix
tablet. The percentage of drug release from formulations F4, F5 and F6 was 99.98%,
98.15% and 92.64% in 24hr respectively. The difference in the drug release profile
of various formulations was due to the presences of different concentrations of
polymer. The cumulative percent of drug release from various formulations and
release coefficients values of the various models for respective formulation were
represented in table no 16.
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Table No 17: Cumulative Percentage drug release of formulations with
combination of polymers (F7-F9)
Time(hr) Cumulative
% drug
release F7
Cumulative
% drug release
F8
Cumulative
% drug release
F9
0 0 0 0
1 4.54 3.84 3.61
2 8.99 7.78 6.99
4 18.29 17.12 16.89
6 26.61 23.45 24.31
8 39.37 36.39 35.21
10 50.45 46.19 44.68
12 62.29 55.47 52.42
14 74.42 68.36 65.85
16 89.58 84.69 80.14
18 93.69 90.27 85.97
20 99.98 94.78 89.67
22 - 99.79 93.41
24 - - 99.74
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Figure No 19: Cumulative percentage drug release of formulations containing
Combination of polymers (F6-F9)
From the above figure no 22 it can be observed that the polymer
HPMC K100 M and Xanthan gum has controlled effect on the release of drug from
the controlled release matrix tablet. The percentage of drug release from
formulations F7, F8, and F9 were 99.98%, 99.79%, and 99.74% in 24hr respectively.
These are the formulations done by combination of polymers. The cumulative
percent of drug release from various formulations and release coefficients values of
the various models for respective formulation were represented in table no 17.
The percentage of drug release from formulations F2, F3, F5, F6 and F9 was
found to be 97.27%, 90.81%, 98.15%, 92.64% and 99.74% in 24 h respectively. The
formulationsF1, F4, F7 and F8 was found to be 90.45%, 92.41%, 93.61% and 90.27%
respectively.
The formulations F1, F4, F7 and F8 were failed to release drug up to 24 hr and
formulation with combination of polymers (HPMC K100 M & XANTHAN GUM)
in 1:1 ratio was released drug 99.74% in 24 hrs.
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Formulation F9 was considered as best formulation among all formulations
and controlled the drug release for desired period of time (24hrs). Hence F9 chosen
for kinetic studies.
7.7 RELEASE KINETICS
Table No 18: Release kinetics of the optimum formulation
Time
(hr)
√T Log T Cumulative
%  drug
dissolved
Cumulative
%  drug un
dissolved
Log
Cumulative
% drug
dissolved
Log
Cumulative
%  drug
Un dissolved
0 0 0 0 100 0 2
1 1 0 3.61 96.39 0.557 1.98
2 1.414 0.301 6.99 93.01 0.844 1.96
4 2.0 0.60 19.57 80.43 1.29 1.90
6 2.44 0.778 25.31 74.69 1.40 1.87
8 2.8 0.90 35.21 64.79 1.54 1.81
10 3.16 1.0 44.68 55.32 1.65 1.75
12 3.46 1.079 52.42 47.58 1.719 1.67
14 3.74 1.146 65.85 34.15 1.818 1.53
16 4.0 1.20 80.14 19.86 1.90 1.29
18 4.2 1.255 85.97 14.03 1.93 1.14
20 4.47 1.30 89.67 10.33 1.95 1.014
22 4.69 1.34 93.41 6.59 1.97 0.818
24 4.89 1.38 99.74 0.26 1.998 -0.585
To know the mechanism of drug release from these formulations, the data
were treated according to zero order (cumulative amount of drug released Vs time),
first-order (log cumulative percentage of drug remaining Vs time), Higuchi’s
(cumulative percentage of drug released Vs square root of time), and Korsmeyer
(log cumulative percentage of drug released Vs log time) equations.
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ZERO ORDER
Figure No 20: Zero order plot of F9 Formulation
FIRST ORDER
Figure No 21: First order plot of F9 Formulation
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HIGUCHI MODEL
Figure No 22: Higuchi Plot for F9 Formulation
KORSEMEYER PEPPAS MODEL
Figure No 23: Korsemeyer Peppas Model ForF9 Formulation
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Table No 19: Release Kinetics of Perindopril Erbumine
Formulation Zero –
Order
R2
First-
Order
R2
Higuchi
R2
Korsemeyer
and peppas
R2 N
F9 0.993 0.738 0.9701 0.6841 0.6045
The in vitro release rate were fitted to Korsemeyer-peppas model and
interpretation of release exponent value (n) enlighten in understanding the release
mechanism from the dosage form. The release exponent value (n) obtained thus
obtained was 0.6045.. The drug release was diffusion controlled as plot of Higuchi’s
model was found to be linear. The F9 formulation exhibited anomalous (non Fickian)
diffusion mechanism.
These Formulations are also showed as highest R2 values of zero order
kinetics indicating the amount of drug from the matrix system were by both
diffusion and erosion.
Selection of optimized batch
The F9 of controlled release matrix tablet was chosen as optimized
formulation because it showed more linearity between the cumulative percentage
perindopril erbumine versus time as indicated by the highest value of the correlation
co-efficient in all selected models, among  controlled release matrix tablet and best
fitted for both Korsemeyer-peppas (0.6841) and zero order (0.993) model.
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7.8 ACCELERATED STABILITY STUDIES
In any rationale design and evaluation of dosage forms for drugs, the stability
of the active component must be major criteria in determining their acceptance or
rejection.
In the present study, stability studies were carried out on formulation F9. The
tablets were stored at 40 ± 20 C and 75 ± 5 % RH for a duration of 3 months and
analysed for their physical parameters, hardness, drug content and friability after 3rd
month the data were showed in table no 20 and % drug release was shown in table
no 21 and figure no 24.
Table No 20:
Characteristic of optimized perindopril erbumine controlled release matrix
tablet
Drug content
(%)
Hardness
(kg/cm2)
Friability
(%)
After one
month 99.70±0.17 4.0±0.115 0.57
After 2nd
months 99.66±0.15 4.0±0.10 0.60
After 3rd
months 99.62±0.15 4.0±0.10 0.63
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Table No 21: In Vitro Dissolution Studies
Time in
hours
Cumulative % drug release
Initial 1stmonth 2ndmonth 3rdmonth
0 0 0 0 0
1 3.61 3.58 3.50 3.46
2 6.99 6.91 6.91 6.87
4 19.57 19.52 19.49 19.45
6 24.31 24.29 24.26 24.20
8 35.21 35.18 35.20 35.18
10 44.68 44.63 44.59 44.54
12 52.42 52.40 52.35 52.30
14 66.85 66.81 66.76 66.65
16 80.14 80.09 80.02 80.00
18 85.97 85.90 85.83 85.78
20 89.67 89.61 89.57 89.52
22 93.41 93.39 93.35 93.31
24 99.74 99.70 99.66 99.62
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Figure No 24: Stability plot of F9 formulation
Accelerated stability studies were carried out at 400 C and 75% RH for three
months. After storage the formulation subjected to drug content, hardness, friability
and in vitro dissolution studies showed no significant change.
There is no much change in accelerated stability studies hence the
formulation F9 was stable.
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8. SUMMARY AND CONCLUSION
 The preformulation parameters like organoleptic properties, angle of repose,
bulk density, tapped density, Hausner’s ratio, carr’s index and
compressibility index of pure drug was evaluated and complied with the
pharmacopoeia specifications.
 FTIR studies showed that there was no interaction between drug and
polymer.
 Controlled release matrix tablets of perindopril erbumine was formulated by
using polymer like HPMC K100 M and Xanthan gum.
 The formulated batches were evaluated for physicochemical parameters and
dissolution profiles. The physical properties like hardness, weight variation
and friability of majority of the batches complied with the pharmacopoeial
specifications. The drug content of all tablets was in the range of 93 – 100%.
 In vitro dissolution study of all the formulations was done in acid buffer pH
1.2 and phosphate buffer pH 6.8. The release rate was faster with Xanthan
gum compared to HPMC.It has been observed that using of combination of
polymers (F9) retarded the drug release up to 24 hrs satisfactorily. The
cumulative % drug release was observed for F9 formulation 99.74.  Hence F9
was taken for kinetic studies.
 The kinetic study was carried out for F9 which showed that the drug release
follows zero order ( regression coefficient 0.993) was adequately controlled
the drug and anomalous non –fickian (N >5) transport of diffusion from the
release from the formulation with complete release in 24hrs made it to select
as an optimized formulation compared with other formulations.
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 The accelerated stability studies were carried out for F9 formulation for 3
months. Data revealed that there was no considerable difference.
 From the above study, concluded that F9 was the optimised formulation
which has shown better drug release in 24hr. However further in vivo studies
can be carried out to support the results.
.
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